Blood-Borne Diseases

Although there have been important improvements to existing vaccines, the list of vaccine-preventable diseases has barely changed at all in over two decades.

Both test vaccines produced immune responses by 1 month after vaccination and the immune response lasted for at least 1 year.

The declaration was made to help direct funds towards controlling the outbreak and providing adult hepatitis A vaccines to those in need.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The ambitious goal of global elimination of the virus by 2030 will take buy-in from all major stakeholders, including the United States.

A recent study found that a sepsis care bundle program implemented in The Mount Sinai Hospital in New York coincided with an increase in antibiotic prescriptions and higher rates of Clostridium difficile infections.

Thoughts leaders believe infectious disease treatment is in the middle of a sea change, moving from antibiotics to antibodies.

Dr. Monique Foster, CDC, and Dr. Eric McDonald, San Diego County Health and Human Services Agency, discuss the surprising return of hepatitis A virus as part of the Late Breakers I symposium.

News about the Zika virus dominated our top articles for the month of September 2017. Did you read them all?

The results of a 5-year study show that coffee drinking can cut down the risk of all-cause mortality in patients with HIV and hepatitis C virus (HCV) infections.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Contagion® will be providing exclusive coverage on the conference, and so, keep your eyes peeled for session coverage and interviews with some of the key presenters.

Officials from the Los Angeles County Department of Public Health declare a local hepatitis A outbreak, as HAV outbreaks continue in San Diego and Santa Cruz.

Case Western Reserve University School of Medicine researchers identify accentuated risks for age-associated comorbidities in those living with HIV.

Phase 3 study shows that combination of elbasvir and grazoprevir is highly efficacious in hepatitis C virus (HCV) infected patients with inherited blood disorders.

Routine, rapid hepatitis C virus (HCV) testing may be a cost-effective method to help decrease the prevalence of new infections in high-risk communities.

The results of a new study have shown that an integrated care (IC) program can be successful in providing treatment to patients infected with hepatitis C virus (HCV) who were unlikely to respond to traditional outreach efforts.

Alex Rinehart, PhD, explains if cabotegravir interacts with any other medications.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Despite clearing the virus, researchers find that Ebola survivors can suffer long-term effects of infection.

Researchers from the Department of Dermatology at the Northwestern University Feinberg School of Medicine have found no correlation between having psoriasis and the prevalence of hepatitis B or C.

The New York State Department of Health warns of potential disease exposure in two facility locations in Westchester County.

A new study suggested that neonatal sepsis, which kills 1 million infants around the world each year, may be prevented with synbiotic treatment.

Shedding light on the perils of faulty personal protective equipment.

Researchers elucidate the prevalence of hepatic steatosis in patients infected with HIV, as well as in patients coinfected with HIV and HCV.

This week we explore whether or not a national state of emergency and criminalizing opioid abuse will really help to stop the problem.

A new study finds that sofosbuvir-based treatment in a real-life setting offered SVR rates greater than 90% in hard-to-treat HCV genotype 3 patients with advanced liver disease.

A recent study suggests that Ebola virus RNA can remain in the genital tract for more than 2 years following the acute infection period.

A recent study finds that the use of sofosbuvir-based direct-acting antivirals for HCV treatment was effective and well-tolerated in elderly patients.

The decision date for a NDA for a new hepatitis B vaccine, Dynavax’s Heplisav-B, has been delayed, as the FDA asked for more post-marketing study information on the vaccine.